0001438943
false
0001438943
2023-08-01
2023-08-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 1, 2023
MALACHITE
INNOVATIONS, INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
000-53832 |
|
75-3268988 |
| (State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
| 200
Park Avenue, Suite 400 |
|
|
| Cleveland,
Ohio |
|
44122 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (216) 304-6556
Not
Applicable
(Former
name or former address, if changed since last report.)
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class: |
|
Trading
Symbol |
|
Name
of each exchange on which registered: |
| Common
Stock |
|
MLCT |
|
OTC
Markets |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
Press
Release
On
August 1, 2023, the Company issued a press release reporting its financial results for the second quarter of 2023.
A
copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The
information in this Item 8.01 (including Exhibit 99.1) is furnished pursuant to Item 8.01 and shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required
to be disclosed solely by Regulation FD.
Portions
of this Current Report may constitute “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks and uncertainties. Although the Company believes any such statements are based on reasonable
assumptions, there is no assurance that the actual outcomes will not be materially different due to a number of factors. Any such statements
are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995.
Additional information about significant risks that may impact the Company is contained in the Company’s filings with the Securities
and Exchange Commission and may be accessed at www.sec.gov. The Company is under no obligation, and expressly disclaims any obligation,
to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Item
9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
MALACHITE
INNOVATIONS, INC. |
| |
|
|
| Dated:
August 1, 2023 |
By: |
/s/
Michael Cavanaugh |
| |
Name:
|
Michael
Cavanaugh |
| |
Title: |
Chief
Executive Officer |
EXHIBIT
INDEX
Exhibit
99.1
MALACHITE
INNOVATIONS REPORTS SECOND QUARTER 2023 RESULTS
CLEVELAND,
OHIO – (August 1, 2023) – MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”), a public company
focused on improving the health and wellness of people and the planet, reported its results for the quarter ended June 30, 2023.
Malachite’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 was filed with the Securities and Exchange Commission on August 1,
2023 and is available for viewing at https://malachiteinnovations.com/investors/. Since the information provided in this press release
is limited to selected financial and operational information, investors and interested parties are encouraged to read Malachite’s
full Form 10-Q available on its website.
Michael
Cavanaugh, Malachite’s CEO, commented, “I am proud to report that the Company has earned positive net income from ordinary
course operations for the very first time in its more than 11-year history as a public company.” Cavanaugh continued, “Additionally,
with our 2Q 2023 results, Malachite has now posted its fourth consecutive quarter of record sales and has generated positive Adjusted
EBITDA of $1,259,642 during the 12-month period ended 2Q 2023, which shatters the prior record of positive Adjusted EBITDA of $412,437
earned during the 12-month period ended 1Q 2023. Although we believe that these early results validate our impact investing strategy
and evince our ability to execute our shareholder value creation plan, our current size and financial performance represents only a small
fraction of our ultimate vision for the Company. Therefore, our entire team remains focused and determined to work every day to create
a truly unique business that helps people and communities, improves the environment, and financially rewards our shareholders.”
Second
Quarter 2023 Financial Highlights
| |
● |
Revenue | $3,998,267 in 2Q 2023 versus $639,359 in 2Q 2022, an increase of $3,358,908, and $11,206,073 in the last 12-month (“LTM”) period ending June 30, 2023 versus $639,359 in the LTM period ending June 30, 2022, an increase of $10,566,714. |
| |
|
|
| |
● |
Gross Profit | $845,101 in 2Q 2023 versus $64,952 in 2Q 2022, an increase of $780,149, and $2,822,403 in the LTM period ending June 30, 2023 versus $64,952 in the LTM period ending June 30, 2022, an increase of $2,757,451. |
| |
|
|
| |
● |
Operating Income (Loss) | $101,759 in 2Q 2023 versus ($423,197) in 2Q 2022, an improvement of $524,956, and ($315,029) in the LTM period ending June 30, 2023 versus ($1,967,318) in the LTM period ending June 30, 2022, an improvement of $1,652,289. |
| |
|
|
| |
● |
Net Income (Loss) | $36,762 in 2Q 2023 versus ($443,186) in 2Q 2022, an improvement of $479,948, and ($371,114) in the LTM period ending June 30, 2023 versus ($1,991,894) in the LTM period ending June 30, 2022, an improvement of $1,620,780. |
| |
|
|
| |
● |
Adjusted EBITDA | $479,405 in 2Q 2023 versus ($367,805) in 2Q 2022, an improvement of $847,210, and $1,259,642 in the LTM period ending June 30, 2023 versus ($1,660,765) in the LTM period ending June 30, 2022, an improvement of $2,920,407. |
| |
|
|
| |
● |
Cash Flow from Operations | ($1,074,195) in 2Q 2023 versus ($450,887) in 2Q 2022, a decline of ($623,308), and ($157,109) in the LTM period ending June 30, 2023 versus ($1,648,111) in the LTM period ending June 30, 2022, an improvement of $1,491,002. |
Second
Quarter 2023 Consolidated Financial Highlights
| | |
2Q 2023 | | |
2Q 2022 | | |
2Q 2023 LTM | | |
2Q 2022 LTM | |
| | |
| | |
| | |
| | |
| |
| Revenue | |
$ | 3,998,267 | | |
$ | 639,359 | | |
$ | 11,206,073 | | |
$ | 639,359 | |
| Cost of Goods Sold | |
| 3,153,166 | | |
| 574,407 | | |
| 8,383,670 | | |
| 574,407 | |
| Gross Profit | |
| 845,101 | | |
| 64,952 | | |
| 2,822,403 | | |
| 64,952 | |
| Operating Expenses | |
| 743,342 | | |
| 488,149 | | |
| 3,137,432 | | |
| 2,032,270 | |
| Operating Income (Loss) | |
| 101,759 | | |
| (423,197 | ) | |
| (315,029 | ) | |
| (1,967,318 | ) |
| Other Income | |
| (64,997 | ) | |
| (19,989 | ) | |
| (56,085 | ) | |
| (24,576 | ) |
| Net Income (Loss) | |
| 36,762 | | |
| (443,186 | ) | |
| (371,114 | ) | |
| (1,991,894 | ) |
| Non-Cash Expenses | |
| 377,646 | | |
| 55,392 | | |
| 1,465,241 | | |
| 306,837 | |
| Working Capital Changes | |
| (1,488,603 | ) | |
| (63,093 | ) | |
| (1,251,236 | ) | |
| 36,946 | |
| Cash Flow from Operations | |
$ | (1,074,195 | ) | |
$ | (450,887 | ) | |
$ | (157,109 | ) | |
$ | (1,648,111 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Gross Profit Margin % | |
| 21.1 | % | |
| 10.2 | % | |
| 25.2 | % | |
| 10.2 | % |
| Operating Profit Margin % | |
| 2.5 | % | |
| -66.2 | % | |
| -2.8 | % | |
| -307.7 | % |
| Net Income Margin % | |
| 0.9 | % | |
| -69.3 | % | |
| -3.3 | % | |
| -311.5 | % |
| Cash Flow from Operations Margin % | |
| -26.9 | % | |
| -70.5 | % | |
| -1.4 | % | |
| -257.8 | % |
Second
Quarter 2023 Segmented Financial Highlights
| | |
2Q 2023 | | |
2Q 2022 | | |
2Q 2023 LTM | | |
2Q 2022 LTM | |
| | |
| | |
| | |
| | |
| |
| Revenue | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 3,882,492 | | |
$ | 639,359 | | |
$ | 11,063,898 | | |
$ | 639,359 | |
| Biochar | |
| – | | |
| – | | |
| – | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 115,775 | | |
| – | | |
| 142,175 | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| – | | |
| – | | |
| – | | |
| – | |
| Total Revenue | |
$ | 3,998,267 | | |
$ | 639,359 | | |
$ | 11,206,073 | | |
$ | 639,359 | |
| | |
| | | |
| | | |
| | | |
| | |
| Gross Profit | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 789,687 | | |
$ | 64,952 | | |
$ | 2,756,566 | | |
$ | 64,952 | |
| Biochar | |
| – | | |
| – | | |
| – | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 55,414 | | |
| – | | |
| 65,837 | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| – | | |
| – | | |
| – | | |
| – | |
| Total Gross Profit | |
$ | 845,101 | | |
$ | 64,952 | | |
$ | 2,822,403 | | |
$ | 64,952 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net Income (Loss) | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 433,922 | | |
$ | (39,429 | ) | |
$ | 1,497,180 | | |
$ | (77,630 | ) |
| Biochar | |
| (19,116 | ) | |
| – | | |
| (38,280 | ) | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 37,550 | | |
| – | | |
| 20,445 | | |
| – | |
| Drug Development | |
| (107,444 | ) | |
| (107,823 | ) | |
| (450,871 | ) | |
| (434,666 | ) |
| Corporate | |
| (308,150 | ) | |
| (295,934 | ) | |
| (1,399,588 | ) | |
| (1,479,598 | ) |
| Total Net Income (Loss) | |
$ | 36,762 | | |
$ | (443,186 | ) | |
$ | (371,114 | ) | |
$ | (1,991,894 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Adjusted EBITDA | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 835,392 | | |
$ | 26,986 | | |
$ | 2,677,681 | | |
$ | (11,215 | ) |
| Biochar | |
| (18,690 | ) | |
| – | | |
| (37,854 | ) | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 40,665 | | |
| – | | |
| 24,988 | | |
| – | |
| Drug Development | |
| (107,444 | ) | |
| (107,823 | ) | |
| (450,871 | ) | |
| (434,666 | ) |
| Corporate | |
| (270,518 | ) | |
| (286,968 | ) | |
| (954,302 | ) | |
| (1,214,884 | ) |
| Total Adjusted EBITDA | |
$ | 479,405 | | |
$ | (367,805 | ) | |
$ | 1,259,642 | | |
$ | (1,660,765 | ) |
Second
Quarter 2023 Reconciliation of Net Income (Loss) to Adjusted EBITDA
| | |
2Q 2023 | | |
2Q 2022 | | |
2Q 2023 LTM | | |
2Q 2022 LTM | |
| | |
| | |
| | |
| | |
| |
| Net Income (Loss) | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 433,922 | | |
$ | (39,429 | ) | |
$ | 1,497,180 | | |
$ | (77,630 | ) |
| Biochar | |
| (19,116 | ) | |
| – | | |
| (38,280 | ) | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 37,550 | | |
| – | | |
| 20,445 | | |
| – | |
| Drug Development | |
| (107,444 | ) | |
| (107,823 | ) | |
| (450,871 | ) | |
| (434,666 | ) |
| Corporate | |
| (308,150 | ) | |
| (295,934 | ) | |
| (1,399,588 | ) | |
| (1,479,598 | ) |
| Total Net Income (Loss) | |
$ | 36,762 | | |
$ | (443,186 | ) | |
$ | (371,114 | ) | |
$ | (1,991,894 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Interest | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 63,061 | | |
$ | 11,023 | | |
$ | 149,185 | | |
$ | 11,023 | |
| Biochar | |
| – | | |
| – | | |
| – | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 224 | | |
| – | | |
| 224 | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| 1,712 | | |
| 8,966 | | |
| 16,106 | | |
| 13,269 | |
| Total Interest | |
$ | 64,997 | | |
$ | 19,989 | | |
$ | 165,515 | | |
$ | 24,292 | |
| | |
| | | |
| | | |
| | | |
| | |
| Taxes | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | – | | |
$ | – | | |
$ | – | | |
$ | – | |
| Biochar | |
| – | | |
| – | | |
| – | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| – | | |
| – | | |
| – | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| – | | |
| – | | |
| – | | |
| – | |
| Total Taxes | |
$ | – | | |
$ | – | | |
$ | – | | |
$ | – | |
| | |
| | | |
| | | |
| | | |
| | |
| Depreciation | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 338,409 | | |
$ | 55,392 | | |
$ | 1,031,316 | | |
$ | 55,392 | |
| Biochar | |
| 426 | | |
| – | | |
| 426 | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 2,891 | | |
| – | | |
| 4,319 | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| – | | |
| – | | |
| – | | |
| – | |
| Total Depreciation | |
$ | 341,726 | | |
$ | 55,392 | | |
$ | 1,036,061 | | |
$ | 55,392 | |
| | |
| | | |
| | | |
| | | |
| | |
| Non-Cash Charges | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | – | | |
$ | – | | |
$ | – | | |
$ | – | |
| Biochar | |
| – | | |
| – | | |
| – | | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| – | | |
| – | | |
| – | | |
| – | |
| Drug Development | |
| – | | |
| – | | |
| – | | |
| – | |
| Corporate | |
| 35,920 | | |
| – | | |
| 429,180 | | |
| 251,445 | |
| Total Non-Cash Charges | |
$ | 35,920 | | |
$ | – | | |
$ | 429,180 | | |
$ | 251,445 | |
| | |
| | | |
| | | |
| | | |
| | |
| Adjusted EBITDA | |
| | | |
| | | |
| | | |
| | |
| Environmental | |
$ | 835,392 | | |
$ | 26,986 | | |
$ | 2,677,681 | | |
$ | (11,215 | ) |
| Biochar | |
| (18,690 | ) | |
| – | | |
| (37,854 | ) | |
| – | |
| Mitigation Banking | |
| – | | |
| – | | |
| – | | |
| – | |
| Security | |
| 40,665 | | |
| – | | |
| 24,988 | | |
| – | |
| Drug Development | |
| (107,444 | ) | |
| (107,823 | ) | |
| (450,871 | ) | |
| (434,666 | ) |
| Corporate | |
| (270,518 | ) | |
| (286,968 | ) | |
| (954,302 | ) | |
| (1,214,884 | ) |
| Total Adjusted EBITDA | |
$ | 479,405 | | |
$ | (367,805 | ) | |
$ | 1,259,642 | | |
$ | (1,660,765 | ) |
Non-GAAP
Financial Information
In
addition to our results under Generally Accepted Accounting Principles (“GAAP”), in this release we also present certain
other supplemental measures of financial performance that are not required by or presented in accordance with GAAP, including Adjusted
Earnings Before Interest Taxes Depreciation and Amortization (“Adjusted EBITDA”). We calculate Adjusted EBITDA as net income
(loss) before interest expense, income tax expense, depreciation and amortization, and non-cash stock-based compensation expenses related
to restricted stock grants and stock options issued to directors and employees and consultants. Adjusted EBITDA is one of the primary
metrics used by management to evaluate our financial performance, analyze the effectiveness of our business strategies, and make budgeting
and capital allocation decisions. However, this non-GAAP measure does have certain limitations and should not be considered as an alternative
to net income (loss), earnings (loss) per share or any other performance measures derived in accordance with GAAP.
About
Malachite Innovations, Inc.
Headquartered
in Cleveland, Ohio, Malachite Innovations, Inc. is a public holding company dedicated to improving the health and wellness of people
and the planet through a novel and innovative approach to impact investing. Malachite owns and operates a balanced portfolio of operating
businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on economically
disadvantaged communities. Malachite takes an opportunistic approach to impact investing by leveraging its competitive advantages and
looking at solving old problems in new ways. Malachite seeks to thoughtfully allocate its capital into ventures that are expected to
make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.
Notice
Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933,
as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely
historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the
future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could
cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others,
the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development,
business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume
no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected
in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report
on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with
the Securities and Exchange Commission.
Malachite
Innovations, Inc.
Investor
Relations
P:
+1 (216) 304-6556
E:
ir@malachiteinnovations.com
W:
www.malachiteinnovations.com
v3.23.2
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Malachite Innovations (PK) (USOTC:MLCT)
過去 株価チャート
から 5 2024 まで 6 2024
Malachite Innovations (PK) (USOTC:MLCT)
過去 株価チャート
から 6 2023 まで 6 2024
